NCT03426748Active, not recruiting
LDR vs. HDR Brachytherapy for Prostate Cancer
A Phase III Randomized Study of Low Dose Rate Compared to High Dose Rate Prostate Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer
Source: ClinicalTrials.gov · Last updated 29 Jan 2026
Brief summary (registry, in English)
H17-02904 is a randomized comparison of low dose rate vs. high dose rate prostate brachytherapy for favorable and intermediate risk prostate cancer suitable for brachytherapy as monotherapy. This is a continuation with expanded accrual of the randomized Pilot study H15-02103
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 140 (actual)
- First submitted
- 2 Feb 2018
- Start date
- 15 Feb 2018
- Primary completion date
- 31 Aug 2026
- Lead sponsor
- British Columbia Cancer Agency
- Diseases
- Prostate cancer
- NCT number
- NCT03426748
What you commit to
- Study type: Interventional
- Participants enrolled: 140
- From 15 Feb 2018 to the primary completion date, 31 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior radical surgery for carcinoma of the prostate,
- Prior pelvic radiation
- Prior chemotherapy for prostate cancer,
- Prior TURP or cryosurgery of the prostate
Other
- Claustrophobic or unable to undergo MRI
Who the study is looking for
- Favorable risk and low-tier intermediate-risk prostate cancer with estimated life expectancy of at least 10 years.
- Clinical stage T1c-T2b, PSA \< 20, Gleason \< 8
- ECOG 0-1
- Low tier intermediate-risk prostate cancer is defined by a single NCCN intermediate risk factor
- Extensive favorable-risk disease is defined as:
- clinical stage T1c-T2a
- PSA \< 10
- Gleason 6
- ≥ 50% of biopsy cores containing cancer
- PSA density \> 0.2 ng/cc
- Selected intermediate risk patients not defined above
- \- T1c/T2a
- \- PSA \< 10
- -Gleason 4+3
- PSA \> 10 and Gleason 3+4
- PSA 10-15 ng/ml and Gleason 4+3
- -\< 33% of cores involved
- -Max tumor length in any core 10 mm
- No androgen deprivation therapy (ADT)
- Prostate volume by TRUS ≤ 60 cc.
- Not eligible for, or accepting of, active surveillance according to NCCN guidelines.
- Signed study specific informed consent.
Age in the registry: 40 years to 80 years · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| British Columbia Cancer Agency Center for the Southern Interior Coordinator of this site? Confirm its status | Kelowna | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.